We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,700
Open access books available

139,000
International authors and editors

175M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Today, multiple myeloma (MM) can be defined as a heterogenous disease composed of different clinical conditions. The differences are a result of patient related factors (age, sex, comorbidity), disease related complications (renal failure, bone disease, neuropathy, thrombosis) and biological characteristics (cytogenetics, lactate dehydrogenase level, plasma cell labelling index, beta2-microglobulin, gene expression profiles). The widely used international scoring system is a powerful tool for determining survival. However, it cannot be used for treatment planning. The biological determinants of disease determined by flourescein in situ hybridization (FISH) and/or conventional cytogenetics are better tools to stratify myeloma subgroups with different survival profiles. Thus these are better tools for designing therapeutic approaches. A risk stratification of newly diagnosed MM according to FISH/Karyotyping has been recently reviewed by Rajkumar (Rajkumar, 2012).

High dose melphalan supported by autologous stem cell transplantation (ASCT) can increase response rates and prolong progression free and overall survival compared to conventional chemotherapies (Attal et al., 1996; Child et al., 2003; Fernand et al., 2005; Koreth et al., 2007). The initial induction regimen is chosen according to whether the patient is eligible or ineligible for a subsequent HDT-ASCT as well as the risk stratification of the patient. Advanced age or significant comorbidity are important limitations for ASCT. High dose therapy has been generally considered for patients ≤ 65 years. However, in medically fit patients, this can be extended up to age 70-75 years. Achievement of high quality responses (VGPR, CR/nCR) at the time of transplantation has been demonstrated to be an early predictor of improved outcomes after ASCT (Harousseau et al., 2009; Chanan-Khan&Giralt, 2010). Elderly patients or patients ineligible for transplantation may also benefit from chemotherapy by achieving high quality responses preferably CR in terms of progression free survival (PFS) and overall survival (OS). As such, the choice of induction therapy is crucial for survival for most patients with MM. The emergence of novel agents (thalidomide, lenalidomide and bortezomib) and
incorporation of these agents into the current induction protocols has increased the rate of CR and at least VGPR before ASCT and significantly improved the OS in MM (Kumar et al., 2008; Kastritis et al., 2009). This opened a new area of debate ‘upfront’ versus ‘delayed’ transplantation. However, current recommendations from experts is that high dose therapy supported by autologous stem cell transplantation (HDT-ASCT) should be the standard of care for eligible patients (Ludwig et al., 2011).

2. Induction therapy for patients eligible for HDT–ASCT

In patients for whom HDT-ASCT is planned, the goal of induction treatment before HDT-ASCT should be to achieve the deepest response preferably up to the level of ≥ VGPR as quickly as possible, to reverse disease related complications and ameliorate patient’s symptoms. The protocol should not induce stem cell toxicity and impair stem cell collection. Hence, it is important to avoid melphalan prior to stem cell collection (Cavo et al., 2011; Ludwig et al., 2011).

Prior to novel agents, the standard of care for patients eligible for ASCT was based on high dose dexamethasone alone or VAD (Vincristine, Adriamycin, high dose dexamethasone). Over the last few years, the emergence of novel agents (thalidomide, bortezomib and lenalidomide) has shifted the choice of induction regimen from conventional VAD or VAD-like regimens to novel-agent containing protocols. In the earlier studies, the combinations of novel agents with high dose dexamethasone were shown to be superior to VAD regimen before ASCT. The more recent trials have concentrated on upfront use of initially 2-drug and more recently 3-drug or even 4-drug combinations applied before ASCT.

2.1. Thalidomide–based regimens

Thalidomide is the first immunomodulatory drug used in the treatment of MM. Apart from the anti-angiogenic activity, this group of drugs also induce apoptosis in myeloma cells. Thalidomide induces responses in MM patients refractory to conventional and even high dose therapy suggesting that it can overcome drug resistance. It may alter the secretion and bioactivity of cytokines (e.g. TNF-α) secreted into bone marrow microenvironment by myeloma and bone marrow stromal cells that induce myeloma cell growth and survival. Thalidomide mediates its immunomodulatory action by induction of Th-1 T cell response with secretion of IFN-Y and IL-2 and regulation of adhesion molecule expression (Hideshima et al., 2000).

After the initial studies showing that single agent thalidomide could produce significant responses and that combination of thalidomide with dexamethasone (TD) results in synergism in refractory/relapsed MM, thalidomide was introduced to the induction therapy for newly diagnosed MM (Singhal et al., 1999; Palumbo et al., 2001). The phase II studies demonstrated the efficacy of TD as front line therapy with 64%-66% response rates (Rajkumar et al., 2002; Cavo et al., 2004). In 2005, a retrospective matched case-control analysis provided the first demonstration of superior rate and depth of response by TD compared with VAD as induction
(≥PR; 76% vs 52%, respectively, p<0.001) (Cavo et al., 2005). Based on the subsequent phase III studies which confirmed the superior response rates achieved with thalidomide containing regimens compared with the conventional induction therapies, TD regimen received an accelerated approval in patients with newly diagnosed MM (Rajkumar et al., 2006; Rajkumar et al., 2008). The summary of the phase II-III studies involving thalidomide-based induction regimens is shown in table-1.

Rajkumar et al. in a randomized double blind placebo-controlled study, provided the first data on significant prolongation of time to progression (TTP) and progression free survival (PFS) with TD compared with dexamethasone alone in patients with newly diagnosed MM (14.9 vs. 6.5 months; p<0.001). However, this study was not powered enough to compare the differences in OS (Rajkumar et al., 2008). Barlogie et al. randomized their patients to receive two cycles of high dose melphalan based chemotherapy each supported with ASCT (Total therapy-2) with or without thalidomide added from outset until disease progression and reported that addition of thalidomide improved the rate of CR and EFS but failed to prolong OS (Barlogie et al., 2006). In a retrospective pair-matched analysis, thalidomide incorporated to induction regimen and continued until the second ASCT revealed significantly improved clinical outcomes and a trend towards extended OS at 5 years (69% vs. 53%; p=0.07) (Cavo et al., 2009). The HOVON-50 trial incorporated doxorubicin to TD (TAD) and compared this regimen with conventional VAD as frontline therapy showing a better response before and after HDT-ASCT (Lokhorst et al., 2008). After long term follow-up, the TAD arm followed by thalidomide maintenance after ASCT was able to induce longer event free survival compared to the VAD arm followed by interferon (34 vs. 22 months; p<0.001) but this did not translate into an improved OS (73 vs. 60 months; p=0.77). Which can be explained by a decreased survival from relapse while on thalidomide maintenance (Lokhorst et al., 2010). A recent MRC Myeloma IX randomized trial compared oral combination therapy CTD (cyclophosphamide, thalidomide, dexamethasone) with oral cyclophosphamide incorporated into conventional VAD (CVAD). Significantly superior response rates were attained with CTD compared with CVAD both after induction and after ASCT. CTD could not significantly prolong PFS or OS but longer followup suggests a trend towards a late OS advantage (Morgan et al., 2012).

Thalidomide does not compromise successful harvest of stem cells. However, it is associated with an increased risk of venous thromboembolism (VTE) and sensory peripheral neuropathy (PNP). Without thromboprophylaxis, the thrombosis risk is 15-17%, which is more frequent during the first 3 months of treatment and warrants prophylactic anticoagulation. Peripheral neuropathy improves within 3-4 months after dose reduction or cessation of the drug in most patients. However, thalidomide induced PNP may be irreversible if appropriate action is not taken when an emerging neuropathy is encountered. Thalidomide at low dose may be effective in the management of patients with renal failure, but close monitoring for complications is required in patients with serious renal and hepatic failure. Major thalidomide toxicities and the summary of the supportive care guidelines regarding the approach to PNP is given in tables 7 and 8, respectively (Beksac et al., 2008; Bird et al., 2011).

It is clearly understood that thalidomide-based regimens have produced better post-induction response rates (≥PR; 63-82.5%) and PFS than conventional high dose dexamethasone based
regimens. However, OS was not prolonged. Poorer response to salvage therapy and decreased survival have been observed in patients who relapsed while on thalidomide. This may be the result of emergence of resistant clones after thalidomide (Rajkumar et al., 2006; Barlogie et al., 2006; Cavo et al., 2009; Lokhorst et al., 2010; Morgan et al., 2012). Thalidomide-dexamethasone is less active and more toxic than lenalidomide-based regimens and not recommended as first line therapy anymore. However, in countries where lenalidomide is not available as initial first line therapy and in patients with renal failure, thalidomide combinations may be preferred. On the other hand, thalidomide is still being investigated in combination with other drugs as induction and maintenance regimens for both transplant eligible and ineligible MM patients.

| Regimen | N | ≥PR % | ≥VGPR % | CR % | ≥PR % | ≥VGPR % | CR % | PFS | OS | Reference |
|---------|---|--------|----------|------|--------|----------|------|-----|----|-----------|
| TD vs. D | 103 | 63 | nr | 4 | nr | nr | nr | nr | nr | Rajkumar 2006 |
| | 104 | 41 | nr | 0 | nr | nr | nr | nr | nr | 5-year 56% 65% |
| TT2 with T vs. | 323 | nr | nr | nr | nr | nr | nr | 62 | Barlogie 2006 |
| TT2 without T | 345 | nr | nr | nr | nr | nr | nr | 43 | |
| TD vs. D | 235 | 63 | 43.8 | 7.7 | nr | nr | nr | 14.9 mos | Rajkumar 2008 |
| | 235 | 46 | 15.8 | 2.6 | nr | nr | nr | 6.5 mos | |
| Double ASCT + T vs. Double ASCT | 135 | 30 | 68 | 31% | 51% | 4-year 5-year | Cavo 2009 |
| | 135 | 15 | 49 | P=0.001 | P=0.07 | |
| TAD vs. VAD | 268 | 71 | 37 | 3 | 84 | 54 | 14 | Median 34 mos 73 mos | Lokhorst 2010 |
| | 268 | 57 | 18 | 2 | 76 | 44 | 12 | Median 22 mos 60 mos | |
| CTD vs.CVAD | 555 | 82.5 | 43 | 13 | 92 | 62% | 50% | Median 27% mos Not reach | Morgan 2012 |
| | 556 | 71 | 27.5 | 8 | 90 | 74% | 37% | Median 25% mos 63% mos | |

ASCT: autologous stem cell transplantation; CTD: cyclophosphamide, thalidomide, dexamethasone; CVAD: cyclophosphamide added to VAD (vincristine, doxorubicin, dexamethasone); nr: not reported; TAD: thalidomide, doxorubicin, dexamethasone; TD: thalidomide, dexamethasone; T: thalidomide, TT2: Total therapy-2. * per-protocol analysis

Table 1. Phase II- III studies of thalidomide-based regimens as induction therapy before HDT-ASCT
2.2. Bortezomib–based regimens

Bortezomib is an effective inhibitor of proteosome. The ubiquitin–proteosome pathway plays an important role in intracellular protein homeostasis by regulating degradation of proteins, including mediators of cell cycle progression and apoptosis. Bortezomib also blocks TNF-α mediated upregulation of NF-KB resulting in decreased binding of myeloma cells to bone marrow stromal cells and results in myeloma cell apoptosis. This activity is observed even in cell lines resistant to conventional anti-myeloma therapies. Bortezomib also cleaves DNA repair enzymes increasing the susceptibility of myeloma cells to DNA damaging agents such as alkylating agents and anthracyclines (Hideshima et al., 2001; Cherry et al., 2012).

Bortezomib received FDA approval in 2003 after showing significant activity in relapsed-refractory MM (Jagannath et al., 2004; Richardson et al., 2005). The initial phase II study of single agent bortezomib in previously untreated MM revealed a response rate of 41% (Richardson et al., 2009). Other phase 2 studies incorporating bortezomib ± dexamethasone to induction regimens were consistent with superior responses ranging from 66% to 95% with 6% to 24% CR rates (Jagannath et al., 2005; Harousseau et al., 2006; Rosinol et al., 2007).

The IFM2005-01 Phase III trial compared VD with VAD as induction before ASCT and lenalidomide was given as post-ASCT maintenance in both arms in a randomized fashion. Post-induction at least VGPR (38% vs 15%) and CR/nCR (15% vs 6%) were superior with VD. This response difference was also maintained after ASCT. However, there was only slight improvement in PFS without an OS benefit. Responses with bortezomib were higher regardless of the disease stage or high-risk cytogenetics (Harousseau et al., 2010).

Popat et al. added doxorubicin at escalating doses (0, 4.5 and 9 mg/m²) to standard dose bortezomib-dexamethasone (PAD) and demonstrated 95% post-induction response rate with 62% high quality responses (≥ VGPR) (Popat et al., 2008). Addition of pegylated-liposomal doxorubicin to bortezomib-dexamethasone revealed similar responses (≥ PR 85% and ≥ VGPR 57.5%) which was further enhanced in patients who underwent ASCT (≥ VGPR 76.6%) (Jakubowiak et al., 2009). A very recent HOVON-65/GMMG-HD4 trial compared pre-transplant PAD (Bortezomib, Adriamycin, Dexamethasone) induction and bortezomib maintenance after ASCT with pre-transplant VAD induction and thalidomide maintenance after ASCT and demonstrated that bortezomib during induction and maintenance significantly improved response rates, quality of response. Similar to other bortezomib containing 3-drug combinations, PFS was significantly improved. Additionally, unlike the other studies, OS was also prolonged in this study (61% vs 55%). Subgroup analysis also indicated that superior outcome with bortezomib was predominantly accomplished in high risk patients presenting with renal failure and del17p (≥ VGPR; 72% vs 43%) (Sonneveld et al., 2012).

Reeder et al. incorporated cyclophosphamide to bortezomib-dexamethasone (CyBorD/VCD) and reported 71% ≥VGPR after 4 cycles and 74% ≥VGPR after ASCT (Reeder et al., 2009). The German Myeloma Study Group reported 84% response rate (≥PR) with 10% CR after 3 cycles of VCD. Over 60% of their patients had high-risk cytogenetics. The response rate in cytogenetically high-risk patients were 83.7% (del13q) and 90% (t(4;14). However, del17p group had lower response rate at 69.2% (Einsele et al., 2009).
These studies demonstrate that bortezomib-based induction studies produce high response rates (≥ PR; 78%-93% and CR 7%-35%) without any adverse effect on stem cell mobilization (Harousseau et al., 2010; Cavo et al., 2010; Rosinol et al., 2012; Sonneveld et al., 2012; Moreau et al., 2010). However, neurotoxicity is a major concern especially when bortezomib is combined with thalidomide. Neurotoxicity can be reduced by reducing bortezomib dose once weekly without affecting the efficacy or by using subcutaneous bortezomib (Mateos et al., 2010). Moreover, Moreau et al. used reduced doses of bortezomib (1 mg/m²) and thalidomide (100 mg/d) in vtD regimen and found that this regimen provided higher VGPR rates compared with VD and the dose reduction of both drugs could resulted in reduced incidence of polyneuropathy (Moreau et al., 2011). Major bortezomib toxicities and the summary of the supportive care guidelines regarding the approach to emerging PNP is given in tables 7 and 8, respectively (Bird et al., 2011).

| Regimen       | N  | After induction | After ASCT | PFS | OS  | Reference            |
|---------------|----|-----------------|------------|-----|-----|----------------------|
|               |    | ≥PR % | ≥VGPR % | CR % | ≥PR % | ≥VGPR % | CR % | Median | 3-year | 3-year |           |
| VD vs. VAD    | 223 | 78.5  | 38     | 15   | 80    | 54      | 35   | 36 mos | 81%    | 77%    | Harousseau 2010 IFM 2005-02 |
|               | 218 | 63    | 15     | 6    | 77    | 37      | 18   | 30 mos | P=0.06 | P=0.5  |           |
| VTD vs. TD    | 236 | 93    | 62     | 31   | 93    | 82      | 55   | 68%    | 3-year | 86%    | Cavo 2010 GIMEMA-MMY 3006 |
|               | 238 | 79    | 28     | 11   | 84    | 64      | 41   | 56%    | P=0.005 | P=0.03 |
| VBMCP/VBAD+V vs. VTD vs. TD | 129 | 75    | 36     | 21   | 73    | 51      | 38   | Median | 38 mos | Np    | Rosinol 2012 PETHEMA/GEM |
|               | 130 | 85    | 60     | 35   | 77    | 65      | 46   | 27 mos | Np    | P=0.006 |
| VAD vs. PAD   | 127 | 62    | 29     | 14   | 58    | 40      | 24   | Not reach. | Np    | GEM |
|               | 413 | 78    | 42     | 7    | 88    | 62      | 21   | 35 mos | 61%    | 55%    | Sonneveld 2012 HOVON65/GMMG HD4 |
|               | 414 | 54    | 14     | 2    | 75    | 36      | 9    | 28 mos | Np    | Np |
| VD vs. vtD    | 99  | 81    | 36     | 31   | 86    | 58      | 22   | Median | 30 mos | Np    | Moreau 2011 IFM2007-02 |
|               | 100 | 88    | 49     | 29   | 89    | 74      | 31   | 26 mos | Np    | P=0.22 |

VD: Bortezomib, dexamethasone; VAD: Vincristine, doxorubicin, dexamethasone; VTD: Bortezomib, thalidomide, dexamethasone; TD: Thalidomide,dexamethasone; VBMCP/VBAD+V: Vincristine, carmustine, melphalan,cyclophosphamide, prednisone/ vincristine, carmustine, doxorubicin, dexamethasone + bortezomib; PAD: Bortezomib, doxorubicin, dexamethasone; vtD: Reduced dose bortezomib, reduced dose thalidomide, dexamethasone; mos: months

Table 2. Phase III studies of bortezomib-based regimens in preparation for HDT-ASCT
Bortezomib has become an important component of therapy for patients with high risk MM associated with del13q and t(4;14) (Richardson et al., 2005; Jagannath et al., 2007). Bortezomib has also proven effective in management of MM patients with renal dysfunction. It has been suggested that in patients with acute renal failure secondary to light chain cast nephropathy VTD can be first choice due to lack of nephrotoxicity. The Mayo Clinic recommends plasma exchange until serum free light chain (FLC)<50 mg/dl and repeated as needed until VTD is fully effective (Rajkumar et al., 2011). Bortezomib is also beneficial for individuals with significant disease related bone-disease due to its inhibitory effect on osteoclastogenesis and stimulatory effect on osteoblast differentiation and proliferation (Zavrski et al., 2005).

### Table 3. Impact of bortezomib incorporated into ASCT on PFS according to cytogenetic abnormalities (Cavo 2012)

| Regimen                  | Progression free survival | Reference          |
|--------------------------|---------------------------|--------------------|
|                          | Overall       | del13q       | t(4;14)       | del(17p)       |                    |
| VD + R ± R vs. VAD + R ± R | 36 mos (median) | nr             | 28mos (median) | 14mos (median) | Avet-Loiseau 2010  |
| VD + R ± R               | 30 mos (median) | nr             | 16mos (median) | nr             |                    |
| PAD + Bort vs. VAD + T   | 48% (at 3-yr) | 40% (at 3-yr) | 28% (at 3-yr) | 22% (at 3-yr) | Sonneveld 2010     |
| VAD + T                  | 40% (at 3-yr) | 29% (at 3-yr) | 20% (at 3-yr) | 16% (at 3-yr) |                    |
| VTD + VTD vs. TD + TD    | 68% (at 3-yr) | 62% (at 3-yr) | 69% (at 3-yr) | nr             | Cavo 2010          |
|                          | 56% (at 3-yr) | 46% (at 3-yr) | 37% (at 3-yr) | nr             |                    |

#### 2.3. Lenalidomide–based regimens

Lenalidomide is another IMID and has more potent in vitro activity; inhibition of angiogenesis, cytokine modulation and T-cell costimulation than thalidomide (Hideshima et al., 2000; Haslett et al., 2003). Lenalidomide primarily triggers the caspase-8 mediated apoptotic pathway and also down-regulates NF-KB activity via a mechanism distinct from bortezomib (Mitsiades et al., 2002). Lenalidomide alone (R) or with dexamethasone (RD) has shown significant activity in relapsed/refractory MM. Responses were observed even in patients in whom thalidomide therapy has previously failed (Richardson et al., 2002). Several phase II studies of lenalidomide and dexamethasone +/- chemotherapy have demonstrated response rates ranging 76-91% (Table-4). In a randomized controlled trial lenalidomide plus high dose dexamethasone (RD) (480 mg/28d cycle) was compared with lenalidomide plus low dose dexamethasone (Rd) (160 mg/28d cycle). Patient enrollment to study was not restricted with age or eligibility for ASCT. In each group lenalidomide was administered as 25 mg/d on 1-21 days. In accordance with others, this study demonstrated that lenalidomide in combination with dexamethasone is an efficient initial therapy for MM. Although RD produced higher response rates, this did not result in superior TTP, PFS or OS compared with Rd. The cause of inferior OS with high dose dexamethasone seems to be related to increased deaths due to toxicity, particularly in first 4 months and in elderly patients. The major grade 3 or higher toxicities including thromboembolic events and infections were significantly higher in the high dose dexamethasone group (Rajkumar et al., 2010). The multicenter, placebo controlled SWOG
trial has confirmed the superiority of lenalidomide in combination with dexamethasone over
dexamethasone alone as initial therapy of MM in terms of response rate and PFS but not in
OS. This study received early closure and open-label lenalidomide and dexamethasone was
made available to all patients (Zonder et al., 2010). In a retrospective case-control study, RD
produced better responses than TD including superior PFS and OS. However, this study was
not a randomized trial and the choice of post-induction therapy was not standardized (Gay et
al., 2010a). Clarithromycin is an antibiotic that has shown efficacy in association with steroids
and both thalidomide and lenalidomide. The same investigators added clarithromycin (Bioxin)
to Rd(BiRd) and compared with Rd in a case-match study. The have reported significantly
better responses with BiRd and the PFS was significantly longer. However, 3- year OS was not
statistically different between the two study arms (Gay et al., 2010).

Lenalidomide can cause myelosuppression and concerns have been raised that its use may
negatively impact the ability to mobilize stem cells in patients who received lenalidomide as
part of their induction therapies (Kumar et al., 2007; Mazumder et al., 2008; Paripati et al.,
2008; Popat et al., 2009). It is suggested that stem cells should be collected within 6 months of
initiation of lenalidomide therapy and the IMWG recommends that patients >65 years or
patients who have received ≥ 4 cycles Rd must undergo stem cell mobilization with cyclo‐
phosphamide + G-CSF or G-CSF + plerixafor (Kumar 2007; Kumar 2009). Dose reduction is
required in presence of renal impairment. Patients may require thromboprophylaxis due to
higher incidence of thromboembolic events. Major lenalidomide toxicities are summarized in
table-10 (Bird et al., 2011).

2.4. Novel agent triplet combinations

To enhance response rates and prolong PFS combination of Bortezomib with an IMID has been
attempted. Bortezomib-thalidomide-dexamethasone (VTD) resulted better response rates and
PFS compared to TD or VD in initial randomized trials (Wang et al., 2005; Cavo et al., 2009).
In a Phase III study of VTD compared with TD as induction before and consolidation after
double ASCT, VTD was superior to TD in all response categories (CR/n CR; 31% vs 11% ;
geVGR; 62% vs 28%) as well as the 3 year estimated PFS (68% vs 56%). Progression free survival
was also superior with VTD compared to TD in poor prognostic groups including del13q,
increased LDH, age≥60 years, t(4;14) ± del17p, increased bone marrow plasma cell ratio and
ISS-II and III (Cavo et al., 2010). The results of the PETHEMA/GEM study also provided a
strong support to VTD as a highly effective induction regimen compared with a combination
chemotherapy containing bortezomib and with TD. Additionally, VTD resulted in a higher
post-transplantation CR rate and a significantly longer PFS. However, this did not result in a
significant prolongation of OS and could not overcome poor prognosis of high-risk cytoge‐
netics (Rosinol et al., 2012).

Synergy has been demonstrated between bortezomib and lenalidomide. Moreover, both
bortezomib and immunomodulatory drugs enhance the activity of dexamethasone. In a phase
I study combining these three agents (RVD) in patients with newly diagnosed MM, the
maximum tolerated dose was set as lenalidomide 25mg/day, bortezomib 1.3mg/m², dexame‐
thasone 20mg/day and in phase II portion of the same study, 100% response rate (≥PR) could
be obtained with ≥VGPR and CR rates 74% and 37%, respectively. This was the first study to result in 100% response rate. The 18-month PFS and OS were 75% and 97%, respectively (Richardson et al., 2010).

In phase II trials the most promising combinations were either lenalidomide or cyclophosphamide with bortezomib and dexamethasone. A phase II study of four-drug combination VDCR, VDR, VDC and VDC-mod (modification of the cyclophosphamide dose) was performed to evaluate the feasibility and activity of these combinations. The response seen with VDCR appear to be similar to those seen with VDR or VDC-mod arms (Table-5). However, the toxicities with VDCR appear to be more than the other arms, especially hematological toxicity. This study does not support an advantage of four drug combination (Kumar et al., 2012).

In another phase I/II study RVD was combined with pegylated-doxorubicin (RVDD) and this regimen was highly active and well-tolerated with response rates ≥PR 96% and 95%, ≥VGPR 57% and 65% after 4 and 8 cycles, respectively (Table-6). After a median 15.5 months follow-up, PFS and OS were not reached. The estimated 18-month PFS and OS were 80.8% and 98.6%, respectively. Among patients who proceeded to ASCT and were evaluable for posttransplant response, response rate further improved reaching 85% of patients ≥VGPR and 61% of those with CR/n CR at 3 months after ASCT. In patients who continued RVDD beyond 4 cycles, depth of response further improved reaching 65% ≥VGPR and 35% CR/n CR at the completion of 8 cycles (Jakuboviak et al., 2011).

| Regimen | N | ≥PR % | ≥VGPR % | CR % | PFS | OS | Reference |
|---------|---|-------|----------|------|-----|----|----------|
| RD | 34 | 91 | 38 | 6 | Median | 2-yr | Rajkumar 2005 |
| RD vs. Rd | 223 | 79 | 42 | | 19 mos | 75% | Rajkumar 2010 |
| | 222 | 68 | 24 | | 25 mos | P=0.026 | 87% |
| RD vs. D | 97 | 78 | | 32% | 3-yr | 79% | Zonder 2010 |
| | 95 | 48 | | | | P=0.28 |
| RD vs. TD | 228 | 80 | 37.8 | 13.6 | Median | Median | Gay 2010 |
| | 183 | 61 | 15 | 3.3 | 17.1 mos | 57.2 mos | P=0.036 | P=0.018 |
| BiRd vs. Rd | 72 | 73.6 | 45.8 | | Median | Median | Gay 2010 |
| | 72 | 33 | 13.9 | | 48.3 mos | 89.7% | P=0.044 | P=0.170 |

Table 4. Results of phase II-III Studies of induction with lenalidomide and dexamethasone
After 4 cycles

|           | VDCR | VDR | VDC | VDC-mod |
|-----------|------|-----|-----|---------|
| N=39      |      |     |     |         |
| CR        | 5%   | 7%  | 3%  | 12%     |
| ≥VGPR     | 33%  | 32% | 13% | 41%     |
| ≥PR       | 80%  | 73% | 63% | 82%     |

Best response across all cycles (median=6 cycles)

|           | VDCR | VDR | VDC | VDC-mod |
|-----------|------|-----|-----|---------|
| N=39      |      |     |     |         |
| CR        | 25%  | 24% | 22% | 47%     |
| ≥VGPR     | 58%  | 51% | 41% | 53%     |
| ≥PR       | 88%  | 85% | 75% | 100%    |

1-yr PFS

|           | VDCR | VDR | VDC | VDC-mod |
|-----------|------|-----|-----|---------|
| N=39      |      |     |     |         |
| CR        | 86%  | 83% | 93% | 100%    |

After censoring patients going to ASCT

|           | VDCR | VDR | VDC | VDC-mod |
|-----------|------|-----|-----|---------|
| N=39      |      |     |     |         |
| 1-yr PFS  | 83%  | 68% | 97% | 100%    |
| 1-yr OS   | 92%  | 100%| 100%| 100%    |

Patients who undergo ASCT

|           | VDCR | VDR | VDC | VDC-mod |
|-----------|------|-----|-----|---------|
| N=39      |      |     |     |         |
| 1-yr PFS  | 100% | 100%| 88% | 100%    |
| 1-yr OS   | 100% | 100%| 100%| 100%    |

Table 5. Results of EVOLUTION Study comparing bortezomib-based multi-drug combinations

|           | N    | Best response after induction (%) | Reference     |
|-----------|------|-----------------------------------|---------------|
| RVD       | 66   | ≥PR 100 ≥ VGPR 67 CR 39           | Richardson 2010 |
| VDCR vs.  | 39   | 88  58 25                          | Kumar 2012    |
| VDR vs.   | 36   | 85  51 24                          |               |
| VDC vs.   | 31   | 75  41 22                          |               |
| VDC-mod   | 16   | 100 53 47                          |               |

Table 6. Phase II Trials of triplet or quadruplet lenalidomide-based induction

| Thalidomide | Lenalidomide | Bortezomib                     |
|-------------|--------------|--------------------------------|
| Venous thromboembolism | Cytopenias | Peripheral neuropathy |
| Sensory peripheral neuropathy | Venous thromboembolism | Gastrointestinal toxicity |
| Constipation | Constipation | Postural hypotension and pre-syncope secondary to autonomic neuropathy |
Table 7. Major toxicities of novel agents

| Grade of neuropathy                      | Bortezomib                                      | Thalidomide                                    |
|------------------------------------------|------------------------------------------------|------------------------------------------------|
| Grade 1                                  | No action                                       | No action                                       |
| Paresthesia, weakness and/or loss of    |                                                |                                                |
| reflexes without pain or loss of         |                                                |                                                |
| function                                 |                                                |                                                |
| Grade 1 with pain or grade 2             | Reduce bortezomib dose to 1 mg/m²                | Reduce thalidomide dose to 50% or              |
| interfering with function but not with    |                                                | suspend thalidomide until                      |
| daily activities                         |                                                | disappearance of toxicity, then               |
|                                          |                                                | reinitiate at 50% dose                        |
| Grade 2 with pain or grade 3             | Suspend bortezomib until                        | Suspend thalidomide until                      |
|                                          | disappearance of toxicity then re-initiate at   | disappearance of toxicity, then               |
|                                          | 0.7 mg/m² and administer once weekly            | reinstate at low dose if PNP grade 1           |
| Grade 4                                  | Discontinue                                     | Discontinue                                    |

Table 8. Guidelines for the management of bortezomib and thalidomide induced PNP

2.5. Conclusions

High dose melphalan supported by autologous stem cell transplantation after novel agent-based induction regimen is the standard of care for patients younger than 65. The quality of response achieved with induction regimens before ASCT affect PFS and potentially the OS. In this regard, the availability of novel anti-myeloma drugs, thalidomide, bortezomib and lenalidomide has improved the pre-transplantation responses. Recent data suggest that 3-drug induction regimens, containing at least one novel agent result in better responses than 2-drug combinations. The results of studies with combinations of VD with either doxorubicin (PAD), cyclophosphamide (CyBorRd), thalidomide (VTD) or lenalidomide (VRD) have demonstrated that the responses can be further enhanced and PFS ± OS can be improved. Within the 3-drug combinations, bortezomib-dexamethasone combined with thalidomide or cyclophosphamide (VTD or VCD) appear to be the most active regimens. So, 3-6 cycles of a triplet bortezomib...
based regimen should be considered the standard induction for patients eligible for ASCT. The objective of treatment should be the achievement of a sustained CR with a good quality of life. Current studies concentrate on best approach to combine available drugs to affect long-term disease control as well as consolidation and maintenance after ASCT and minimize the long-term toxicities, especially neurotoxicity. Bortezomib is effective not only in patients with standard risk disease but also in the presence of high risk cytogenetic abnormalities especially in presence of t(4;14). Current question under evaluation is whether to apply or delay ASCT when a CR is achieved with a novel agent induction treatment.

3. Induction therapy for patients ineligible for HDT–ASCT

Melphalan was the first alkylating agent used for treatment of MM and melphalan–prednisone (MP) has been the standard therapy for over 30 years although it yielded only PR in 40-60% of patients with CR <5% and PFS about 18 months and OS 2-3 years. Trials comparing MP with high dose dexamethasone-based combinations revealed no survival advantage (Mateos et al., 2012). During the last decade, with the emergence of novel agents and the studies revealing the importance of achieving VGPR/CR on survival of myeloma patients, the historical goals of induction have changed to achieving a high quality response in elderly patients as well.

3.1. Bendamustine

Bendamustine is a novel bifunctional drug which has similarities to both alkylating agents and purine analogs. It has promising activity in low grade lymphoid malignancies. The East German Study Group conducted a phase III trial comparing bendamustine and prednisone (BP) with standard MP in previously untreated patients with MM who are ineligible for transplantation. Bendamustine –prednisone was superior to MP with respect to CR rate (32% vs 13%, p=0.007) and TTF (14 mos vs 10 mos, p=0.02). There was no significant difference with regard to OS between the two treatment groups and the toxicity profile was comparable (Pönisch et al., 2006). Mainly based on the results of this study, bendamustine is currently approved for treatment of newly diagnosed MM patients who are not candidates for HDT-ASCT and who can not receive thalidomide or bortezomib due to peripheral neuropathy. The same investigators in a recent study demonstrated that bendamustine in combination with bortezomib and prednisone (BPV) is also effective in patients with newly diagnosed MM and renal failure. Eighty-three percent of the patients treated with this protocol responded to therapy and 72% had their renal function improved after treatment (Pönisch et al., 2012).

3.2. Thalidomide–based regimens

Thalidomide incorporated in to the MP regimen (MPT) has been compared with the standard MP regimen in six randomized phase III studies. Each protocol had some minor differences in their schedules which is shown in table-9. The overall response rate (57%-76%) with MPT was significantly higher than MP (31%-48%). The CR rates with MPT ranged between 7%-13%, one study reported ≥ VGPR rate as 27%. In the IFM-I/II studies and in HOVON study, the prolong-
gation in the PFS with MPT was also translated in to OS advantage (Facon et al., 2007; Hulin et al., 2009; Wijermans et al., 2010). Despite in the other three studies the PFS advantage was not translated into OS advantage (Palumbo et al., 2008; Waage et al., 2010; Bekscak et al., 2011), a metaanalysis of the pooled data of 1682 patients from these six trials showed that the addition of thalidomide to MP improves OS and PFS in previously untreated elderly patients with multiple myeloma, extending the median survival time by on average 20%. In this metaanalysis, median PFS was prolonged by 5.4 months (HR 0.67 (0.55-0.80) p<0.0001) and the median OS was prolonged 6.6 months (HR 0.82 (0.66-1.02) p=0.004) (Fayers et al., 2011). This improvement was less pronounced in patients aged ≥ 75 years and no favorable effect of thalidomide on OS in this population could be demonstrated. The most frequent grade 3-4 adverse events with MPT protocol were polyneuropathy (6-23%) and VTE (3-12%), infections (10-13%), cardiac complications (2-7%), gastrointestinal events (5%). The discontinuation rate ranged 16-45% (Hulin et al., 2009; Wijermans et al., 2010; Fayers et al., 2011). Based on these results, MPT became one of the new standard therapies for elderly patients with newly diagnosed MM.

Thalidomide-dexamethasone (TD) combination was also compared with MP in 289 elderly patients with MM. Patients achieving stable disease or better were randomly assigned to maintenance therapy with either thalidomide 100 mg daily or interferon alpha-2b. Thalidomide-dexamethasone resulted in a higher proportion of ≥VGPR (26% vs 13%; P=.006) and ORR (68% vs 50%; P=.002) compared with MP. However, PFS was similar (16.7 vs 20.7 months; P=1) and OS was significantly shorter in the TD group (41.5 vs 49.4 months; P=.024). Decreased survival was more evident in patients older than 75 years due to increased non-disease related deaths during the first year (Ludwig et al., 2009). Combinations with high dose dexamethasone is not recommended for elderly patients especially those ≥ 75 years due to increased toxicity. In a randomized MRC Myeloma IX trial, cyclophosphamide, thalidomide and dexamethasone (CTDa) in which dexamethasone dose was reduced, produced higher response rates than MP but was not associated with improved PFS and OS. Additionally, CTDa was associated with higher rates of adverse events compared to MP (Morgan et al., 2011).

### 3.3. Bortezomib–based regimens

After showing significant efficacy in relapsed-refractory myeloma, bortezomib was also incorporated into trials for initial therapy of MM in transplant ineligible patients. The clinical value of adding bortezomib to the standard MP regimen (VMP) was explored in Velcade as Initial Standard Therapy (VISTA) Study (San Miguel et al., 2008). In this phase III study, 682 newly diagnosed myeloma patients were randomly assigned to receive nine 6-week cycles of melphalan (9 mg/m2) and prednisone (60 mg/m2) on days 1 to 4, either alone or with bortezomib (1.3 mg/m2) on days 1, 4, 8, 11, 22, 25, 29 and 32 during cycles 1 to 4 and on days 1, 4, 8, 22, and 29 during cycles 5 to 9. Addition of bortezomib to MP significantly improved all responses, PFS as well as the OS (Table-10). The main adverse events associated with VMP were neutropenia (40%), thrombocytopenia (37%), peripheral neuropathy (14%), infection (10%) and gastrointestinal events (7%). A recent update of the VISTA study and a subsequent study showed that grade 3-4 hematological and non-hematological adverse events in partic-
ular PNP as well as discontinuation of the drug was significantly reduced without affecting the efficacy when once weekly bortezomib schedule was used (Mateos et al., 2010a; Brignhen et al., 2010). In the VISTA trial, patients with high risk cytogenetic profile had similar response rate and OS with the patients with standard risk profile suggesting that addition of bortezomib may overcome the poor prognosis confered to high risk cytogenetics. Another important point of this study was that first-line bortezomib use did not induce more resistant relapse unlike

| Regimen         | N   | Schedule                      | ORR% | CR%  | TTP (months) | OS (median) | Reference          |
|-----------------|-----|-------------------------------|------|------|--------------|-------------|--------------------|
| MPT+T(until PD) | 129 | M: 4mg/m2, d1-7               | 76   | 16   | 22           | 45          | GIMEMA            |
|                 |     | P: 40mg/m2, d1-7, T: 100mg/d  | 48   | 2.4  | p=0.004      | 47.6        | Palumbo 2008      |
|                 |     | 6 cycles every 4 wks until relapse | | | p=0.79 | | |
| MP              | 126 |                               |      |      |              |             |                   |
| MPT+T(until PD) | 125 | M:0.25mg/kg, d1-4             | 76   | 13   | 28           | 52          | IFM-I             |
|                 |     | P: 2mg/kg, d1-4, T:100-400mg/d| 35   | 2    | 18           | P=0.0006    | Facon 2007        |
|                 |     | 12 cycles every 6 wks         |      |      |              |             |                   |
| MP              | 196 |                               |      |      |              |             |                   |
| MPT+T(until PD) | 148 | M:0.25mg/kg, d1-4             | 57   | 13   | 15           | 29          | NMSG              |
|                 |     | P: 1mg/kg, d1-5, T:200-400mg/d| 40   | 4    | 14           | P=0.001     | Waage 2010        |
|                 |     | Until plateau every 6 wks     |      |      |              |             |                   |
|                 |     | Maintenance T 200mg           |      |      |              |             |                   |
| MP              | 179 |                               |      |      |              |             |                   |
| MPT+T(until PD) | 165 | M:0.25mg/kg, d1-5             | 66   | 27   | 13           | 40          | HOVON             |
|                 |     | P: 1mg/kg, d1-5, T:200mg/d    | 45   | 10   | ≥VGPR        | P=0.001     | Wijermans 2010    |
|                 |     | 8 cycles every 4 wks          |      |      | PFS          | P=0.05      |                   |
|                 |     | Maintenance T 50mg            |      |      |              |             |                   |
| MP              | 168 |                               |      |      |              |             |                   |
| MPT             | 62  | M: 9mg/m2, d1-4               | 58   | 9    | 21           | 26          | TMSG              |
|                 |     | P: 60mg/m2, d1-4, T: 100mg/d  | 38   | 9    | 14           | P=0.34      | Beksac 2011       |
|                 |     | 8 cycles every 6 wks          |      |      |              | P=0.65      |                   |
| No maintenance  | 60  |                               |      |      |              |             |                   |

M:Melphalan; P:Prednisone; T:Thalidomide; PD:Progressive disease; PFS:Progression free survival; DFS: Disease free survival; GIMEMA: Italian Myeloma Network; IFM: Intergroupe Francophone du Myé´lome; NMSG: Nordic Myeloma Study Group; HOVON: Dutch-Belgium Hemato-Oncology Cooperative Group; TMSG: Turkish Myeloma Study Group

Table 9. Phase III Studies comparing MPT versus MP for newly diagnosed MM ineligible for HDT-ASCT
that is seen in thalidomide relapses. The survival data of the VISTA trial was updated at 3 years and 5 years and the survival benefit of VMP protocol remained significant (Mateos et al., 2010a; San Miguel et al., 2011). A part of the VISTA trial investigated the efficacy of VMP protocol in renal impairment excluding patients with Cr >2mg/dl. Response rates with VMP and TTP in both arms did not appear significantly different between patients with GFR ≤ 50 or > 50 mL/min. Moreover, VMP resulted in 44% renal impairment reversal suggesting that this protocol is also an active and well-tolerated treatment option for patients with moderate renal impairment (Dimopoulos et al., 2009).

|            | VMP (N=344) | MP (N=338) | p     | References      |
|------------|-------------|------------|-------|-----------------|
| ORR (≥PR) | 71%         | 35%        | <0.001| San Miguel 2008 |
| CR         | 30%         | 4%         | <0.001|                 |
| TTP        | 24 mos      | 16.6 mos   | <0.001|                 |
| OS         | Median follow-up 16.3 mos | 0.008 | HR=0.61 |
| OS         | Median follow-up 36.7 mos | Not reached | 43 mos | <0.001 | HR=0.653 | Mateos 2010 |
| OS         | Median follow-up 60 mos | 56.4 mos | 43.1 mos | 0.0004 | HR=0.695 | San Miguel 2011 |
| 3-yr OS    | 68.5%       | 54%        |       |                 |

Table 10. Results of the VISTA trial and the long-term follow-up

In the PETHEMA trial Mateos et al. have demonstrated that reduced intensity induction with a bortezomib based regimen followed by maintenance is a safe and effective treatment. The investigators compared VMP with VTP (bortezomib, thalidomide, prednisone) as initial therapy in newly diagnosed patients with MM ineligible for transplantation. In both protocols, a reduced intensity bortezomib schedule consisting of one cycle of bortezomib twice per week for 6 weeks followed by five cycles of bortezomib once per week for 5 weeks was used. Patients who completed the six induction cycles were randomly assigned to maintenance therapy with bortezomib plus prednisone (VP) or bortezomib plus thalidomide (VT). The response rates were higher with VTP compared to VMP (CR 28% vs 20%; ORR 81% vs 80%). Maintenance with VT significantly improved time to progression compared with that for patients who received VP. The support to better response rates with VTP also came from the initial results of UPFRONT study which compared VD, VTD and VMP and revealed better response rates.
with VTD (Table-11). On the other hand, in both studies patients treated with VTP had more frequent serious adverse events especially PNP and thrombosis (Mateos et al., 2010b; Nievizsky et al., 2011). Combining four drugs (bortezomib, melphalan, prednisone, thalidomide) followed by maintenance with bortezomib-thalidomide (VMPT-VT) was superior to VMP alone in patients with MM who are ineligible for autologous stem-cell transplantation. The 3-years PFS was also improved with VMPT-VT. However, no significant difference in 3-year OS was observed. Additionally, grade 3 to 4 neutropenia, cardiologic events and thromboembolic events were more frequent among patients assigned to the VMPT-VT group than among those assigned to the VMP group (Palumbo et al., 2010). Due to significantly increased adverse events with 4-drug regimen, VMP or MPT are better alternatives for induction of elderly myeloma patients.

|                  | N   | ORR % | CR % | PFS            | OS             | Reference       |
|------------------|-----|-------|------|----------------|----------------|----------------|
| **VMP**          | 130 | 80    | 20   | 37 mos         | 60 mos median  | Mateos 2010    |
| VTP with maintenance VP or VT | 130 | 81    | 28   | 32 mos         | 5-yr 53%       |                |
| **VMPT + VT**    | 254 | 89    | 38   | 3-year         | 3-year         | Palumbo 2010   |
| VMP + no maintenance | 257 | 81    | 24   | 56%            | 89%            |                |
|                  |     |       |      | P<0.001        | 41% p=0.008    |                |
| **VD**           | 168 | 73    | 24   | NA             | NA             | Nievizsky 2011 |
| **VTD**          | 167 | 80    | 36   | NA             | NA             |                |
| **VMP**          | 167 | 69    | 31   | NA             | NA             |                |

VD: Bortezomib dexamethasone; VTD: Bortezimib, thalidomide, dexamethasone; VMP: Bortezomib, melphalan, prednisone; VT: Bortezomib, thalidomide; mos: months; NA: Not available

**Table 11. Phase III Studies comparing bortezomib containing regimens**

### 3.4. Lenalidomide–based regimens

In a randomized controlled trial lenalidomide (25 mg/d on d 1-21) plus high dose dexamethasone (480 mg/28d cycle) (RD) produced higher response rates compared with lenalidomide (25 mg/d on d 1-21) plus low dose dexamethasone (Rd) (160 mg/28d cycle). However, this did not translate into superior PFS (Median 19.1 months vs 25.3 months). Moreover, Rd was associated with significantly improved 1-year OS than with RD (96% vs 87%, p=0.0002) and treatment related toxicity was significantly reduced. The cause of inferior OS with high dose dexamethasone seems to be related to increased deaths due to toxicity particularly in first 4 months and in elderly patients. Hence, the advantages of Rd over RD were more pronounced in patients aged > 70 years (Rajkumar et al., 2010; Zonder et al., 2010). A recent double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide
(MPR) or melphalan-prednisone (MP) followed by placebo. Response rates were superior with MPR-R compared with MPR or MP (ORR, 77% vs 68% vs 50%; CR, 18% vs 13% vs 5%; respectively). MPR-R significantly prolonged PFS in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. This study also underlines the importance of lenalidomide maintenance after MPR induction as another treatment option for elderly myeloma patients. The toxicity profile was excessive for frail patients, which negatively affected the efficacy. Main grade 3-4 adverse events of MPR were neutropenia (52-71%), thrombocytopenia (23-38%), infections (10%) and thromboembolism (5%) (Palumbo et al., 2012).

| Various circumstances                                      | Suggestions                                    |
|------------------------------------------------------------|------------------------------------------------|
| Rapid reversal of spinal cord compression or renal impairment | Bortezomib                                    |
| Pre-existing neuropathy                                    | Lenalidomide (MPR, Rd) or bendamustin (BP)     |
| History of venous thromboembolism                           | Bortezomib                                    |
| In cases with renal failure                                | Thalidomide, bortezomib, bendamustin can be administered at full dose, Lenalidomide requires dose reduction according to creatinin clearance |
| Contraindications to use of alkylating agents such as presence myelodysplasia or increased risk of myelosuppression | TD or VD can be used instead of MP |
| Frail patients                                              | Prednisone is better tolerated than dexamethasone |

Table 12. Individualized treatment strategies for non-transplant candidate patients

It is clear that the novel agents have prolonged the survival of patients with MM. However, this benefit is more pronounced in younger patients. Age has been reported to be a negative prognostic factor. It is not because the elderly patients have biologically different disease but because they can not tolerate high intensity therapy protocols, have lower bone marrow reserves, increased tendency for infections and also difficulty in recovering from infections and have more frequent drug toxicities. A patient’s overall physical condition, fraility, comorbidity and disability should be assessed before starting therapy in order to choose the appropriate treatment protocol and dosing. These terms are fully explained in a review by Palumbo et al (Palumbo A et al. 2011). Although the novel agents offer important survival for patients with MM, the incidence of grade 3-4 adverse events and drug discontinuations are significantly higher with combination regimens that are based on novel agents than with traditional chemotherapy regimens. It has been suggested that modifying drug doses at the start of therapy and management of adverse events during the therapy improves tolerability so that the patients can receive the drugs for a longer time to get survival benefit. Secondly, the tolerability of treatment can be further improved with full supportive therapy with bisphosphonates, antivirals, anticoagulants, growth factors and appropriate pain control.
3.5. Conclusions

At present, the induction regimen for patients ineligible for HDT/ASCT is either MP or high/low dose of Dexamethasone combined with one of the three novel agents (thalidomide or bortezomib or lenalidomide). Selection between these combinations depends on the patients’ presenting symptoms such as presence of neuropathy, renal impairment or the rapidity required to reverse the symptoms. In countries where lenalidomide is not yet allowed as first line therapy, induction can be started with thalidomide or bortezomib containing triple regimens and in case of unresponsiveness or intolerability, lenalidomide can be used as second line therapy. Fraility, comorbidity and disability of the elderly patients should be taken into account before choosing the induction protocol and appropriate dose reductions should be done. Thus, the treatment should be individualized. Melphalan-based regimens are used for a fixed duration (9-18 months) and then observed. However, the duration of treatment with revlimid (Rd) is unclear either continue until relapse or a fixed duration of 18 months has been tested in ongoing phase III trials. Evidence is now emerging that maintenance or continuous therapy with novel agents is improving PFS with a potential to improve OS. However, in elderly patients, it is particularly important to start treatment at a dose that can be tolerated over the long term. Specific recommendations yet can not be made regarding the impact of novel treatment regimens on prognosis of elderly patients with high-risk cytogenetics. Although the Italian study (Palumbo et al., 2010) suggested some PFS benefit in response to VMPT+VT over VMP regarding the high-risk cytogenetics, other studies did not confirm this.

| Regimen                      | Usual dosing schedule                                      | Reference            |
|------------------------------|------------------------------------------------------------|----------------------|
| Melphalan-Prednisone (MP-7 day Schedule) | Melphalan 8-10 mg oral days 1-7  
Prednisone 60mg/d oral days 1-7  
Repeated every 6 weeks | Kyle et al., 2004 |
| Thalidomide-Dexamethasone (Td) | Thalidomide 200 mg oral days 1-28  
Dexamethasone 40 mg oral days 1,8,15,22  
Repeated every 4 weeks | Rajkumar et al., 2006 |
| Lenalidomide-Dexamethasone (Rd) | Lenalidomide 25 mg oral days 1-21  
Dexamethasone 40 mg oral days 1,8,15,22  
Repeated every 4 weeks | Rajkumar et al., 2010 |
| Bortezomib –dexamethasone (Vd) | Bortezomib 1.3 mg/m² iv days 1,8,15,22  
Dexamethasone 20 mg on day of and day after bortezomib  
(or 40 mg days 1,8,15,22)  
Repeated every 4 weeks | Harousseau et al., 2006 |
| Melphalan-Prednisone-Thalidomide (MPT) | Different MPT protocols are described in table… |
| Regimen | Usual dosing schedule | Reference |
|---------|-----------------------|-----------|
| Bortezomib-Melphalan-Prednisone (VMP) | Bortezomib 1.3 mg/m² iv days 1,8,15,22  Melphalan 9 mg/ m² oral days 1-4  Prednisone 60 mg / m² oral days 1-4  Repeated every 35 days | San Miguel et al., 2008 |
| Bortezomib-Thalidomide-Dexamethasone (VTD) | Bortezomib 1.3 mg/m² iv days 1,8,15,22  Thalidomide 100-200 mg oral days 1-21  Dexamethasone 20 mg on day of and day after bortezomib (or 40 mg days 1,8,15,22)  Repeated every 4 weeks | Cavo et al., 2009 |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBoRd) | Cyclophosphamide 300mg/ m² oral days 1,8,15,22  Bortezomib 1.3 mg/m² iv days 1,8,15,22  Dexamethasone 40 mg oral days 1,8,15,22  Repeated every 4 weeks | Reeder et al., 2009 |
| Bortezomib-Cyclophosphamide-Dexamethasone (VCD) | Bortezomib 1.3 mg/m² iv days 1,4,8,11  Cyclophosphamide 900mg/ m² on day 1 every 3 weeks  Dexamethasone 40 mg on day of and day after bortezomib | Einsele et al., 2009 |
| Bortezomib-Lenalidomide-Dexamethasone (VRD) | Bortezomib 1.3 mg/m² iv days 1,8 and 15  Lenalidomide 25 mg oral days 1-14  Dexamethasone 20 mg on day of and day after bortezomib (or 40 mg days 1,8,15,22)  Repeated every 3 weeks | Richardson et al., 2010 |
| Bortezomib-Melphalan-Prednisone-Thalidomide (VMPT) | Bortezomib 1.3 mg/m² iv days 1,8,15,22 every 35 days  Melphalan 9 mg / m² oral days 1-4 every 35 days  Prednisone 60 mg / m² oral days 1-4 every 35 days  Thalidomide 50 mg/day | Palumbo et al., 2010 |
| Melphalan-Prednisone-Lenalidomide (MPR-R) | Melphalan 0.18 mg/kg on days 1-4 every 4 weeks x 9 cycles  Prednisone 2mg/kg on days 1-4 every 4 weeks x 9 cycles  Lenalidomide 10 mg on days 1-21 then 10mg/d until relapse | Palumbo et al., 2012 |
| Cyclophosphamide-Thalidomide-Dexamethasone (atenuated dose) (CTD a) | Cyclophosphamide 500mg/week  Thalidomide 50 mg/day for 4 weeks, 50 mg increments every 4 weeks to a maximum 200mg/day  Dexamethasone 20 mg/day on days 1-4 and 15-18 every 4 weeks | Morgan et al., 2011 |
| Bortezomib-Lenalidomide-Dexamethasone-Cyclophosphamide (VRDC) | Bortezomib 1.3 mg/m² iv days 1,4,8,11  Lenalidomide 15 mg oral days 1-14  Dexamethasone 40 mg days 1,8,15  Cyclophosphamide 500mg/ m² days 1,8 | Kumar et al., 2010 |

Table 13. Main treatment protocols in Multiple Myeloma
Author details

Sule Mine Bakanay¹ and Meral Beksac²

¹ Ataturk Hospital, Hematology Unit, Ankara, Turkey
² Ankara University School of Medicine, Department of Hematology, Ankara, Turkey

References

[1] Anderson, K. C, Jagannath, S, Jakubowiak, A, Lonial, S, Raje, N, Alsina, M, Ghobrial, I, & Knight, R. Esseltine D & Richardson J Clin Oncol, abstr 8536., 2009.

[2] Attal, M, Harousseau, J. L, Stoppa, A. M, Sotto, J. J, Fuzibet, J. G, Rossi, J. F, Casassus, P, Maisonneuve, H, Facon, T, & Ifrah, N. Payen C & Bataille R. ((1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med., 11;, 335(2), 91-7.

[3] Avet-loiseau, H, Leleu, X, Roussel, M, Moreau, P, Guerin-charbonnel, C, Caillot, D, Marit, G, Benboubker, L, Voillat, L, Mathiot, C, Kolb, B, Macro, M, Campion, L, Wetterwald, M, Stoppa, A. M, Hulin, C, Facon, T, & Attal, M. Minvielle S & Harousseau JL. ((2010). Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol.,, 28(30), 4630-4.

[4] Barlogie, B, Tricot, G, Anaissie, E, Shaughnessy, J, Rasmussen, E, Van Rhee, F, Fassas, A, Zangari, M, Hollmig, K, Pineda-roman, M, Lee, C, Talamo, G, Thertulien, R, Kiwan, E, Krishna, S, Fox, M, & Crowley, J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. (2006). Mar 9;, 354(10), 1021-30.

[5] Beksac, M. Delforge M & Richardson The evolving treatment paradigm of multiple myeloma: From past to present and future. Turk J Hematol., 25(2): 60-70., 2008.

[6] Beksac, M, Haznedar, R, Fıratlı-tuglular, T, Ozdогu, H, Aydoğdu, İ, Konuk, N, Sučak, G, Kaygusuz, İ, Karakus, S, Kaya, E, Ali, R, Gulbas, Z, & Ozet, G. Goker H & Undar L. ((2011). Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol.,, 86(1), 16-22.

[7] Bird, J. M, Owen, R. G, Sa, D, Snowden, S, Pratt, J. A, Ashcroft, G, Yong, J, Cook, K, Feyler, G, Davies, S, Morgan, F, Cavenagh, G, Low, J, Behrens, E, & Haematology- Oncology, J. Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. ((2011). Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol.,, 154(1), 32-75.
[8] Bringhen, S, Larocca, A, Rossi, D, Cavalli, M, Genuardi, M, Ria, R, Gentili, S, Patriarca, F, Nozzoli, C, Levi, A, Guglielmelli, T, Benevolo, G, Callea, V, Rizzo, V, Cangiati, C, Musto, P, De Rosa, L, Liberati, A. M, Grasso, M, Falcone, A. P, Vangelista, A, Cavo, M, & Gaidano, G. Boccadoro M & Palumbo A. ((2010). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 116(23), 4745-53.

[9] Cavo, M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P & Baccarani M. ((2009). Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol., 27(30), 5001-7.

[10] Cavo, M, Rajkumar, S. V, Palumbo, A, Moreau, P, Orlofski, R, Bladé, J, Sezer, O, Ludwig, H, Dimopoulos, M. A, Attal, M, Sonneveld, P, Boccadoro, M, Anderson, K. C, Richardson, P. G, Bensinger, W, Johnsen, H. E, Kroeger, N, Ghahrtin, G, Bergsagel, P. L, Vesole, D. H, Einsele, H, Jagannath, S, Niesvizky, R, & Durie, B. G. San Miguel J & Lonial S; International Myeloma Working Group. ((2011). International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood,, 117(23), 6063-73.

[11] Cavo, M, Tacchetti, P, Patriarca, F, Petrucci, M. T, Pantani, L, & Galli, M. Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescostra N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P & Baccarani M; GIMEM Italian Myeloma Network. ((2010). Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376(9758), 2075-85.

[12] Cavo, M, Zamagni, E, Tosi, P, Cellini, C, Cangini, D, Tacchetti, P, Testoni, N, Tonelli, M, De Vivo, A, & Palareti, G. Tura S & Baccarani M. ((2004). First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica,, 89(7), 826-31.

[13] Cavo, M, Zamagni, E, Tosi, P, Tacchetti, P, Cellini, C, Cangini, D, De Vivo, A, Testoni, N, Nicci, C, Terragna, C, Grafone, T, Perrone, G, & Ceccolini, M. Tura S & Baccarani M; Bologna 2002 study. ((2005). Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 106(1), 35-9.

[14] Chanan-Khan AA & Giralt S(2010). Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol., 28(15), 2612-24.

[15] Cherry, B. M, Korde, N, & Kwok, M, Roschewski M & Landgren O. ((2012). Evolving therapeutic paradigms for multiple myeloma: back to the future. Leuk Lymphoma. [Epub ahead of print].
[16] Child, J. A, Morgan, G. J, Davies, F. E, Owen, R. G, Bell, S. E, Hawkins, K, & Brown, J. Drayson MT & Selby PJ; Medical Research Council Adult Leukaemia Working Party. ((2003). Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med, 8;, 348(19), 1875-83.

[17] Dimopoulos, M. A, Richardson, P. G, Schlag, R, Khuageva, N. K, Shpilberg, O, Kasttritis, E, Kropff, M, Petrucci, M. T, Delforge, M, Alexeeva, J, Schots, R, Masszi, T, Mateos, M. V, Deraedt, W, Liu, K, & Cakana, A. van de Velde H & San Miguel JF. ((2009). VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol.,, 27(36), 6086-93.

[18] Einsele, H, Liebisch, P, Langer, C, et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM Xla Trial). ((2009). ASH Annual Meeting Abstracts. Abstract 131.

[19] Facon, T, Mary, J, Y, Hulin, C, Benboubker, L, Attal, M, Pégourie, B, Renaud, M, Harousseau, J. L, Guillerm, G, Chalet, P., Dib, M, Voillat, L, Maisonneuve, H, Trony, J, Dorvaux, V, Moncoqué M, Martin, C, Casassus, P, Jaubert, J, Jardel, H, Doyen, C, Kolb, B, Anglaret, B, Grosbois, B, & Yakoub-aga, I. Mathiot C & Avet-Loiseau H;Intergroupe Francophone du Myélome. ((2007). Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, , 370(9594), 1209-18.

[20] Fayers, P. M, Palumbo, A, Hulin, C, Waage, A, Wijermans, P, Beksaç, M, Bringen, S, Mary, J. Y, Gimsing, P, Termorshuizen, F, Haznedar, R, Caravita, T, Moreau, P, Tur-esson, I, Musto, P, Benboubker, L, & Schaafsma, M. Sonneveld P & Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergruppe Francophone du Myélome; European Myeloma Network. ((2011). Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood, , 118(5), 1239-47.

[21] Fermand, J. P, Katsahian, S, Divine, M, Leblond, V, Dreyfus, F, Macro, M, Arnulf, B, Royer, B, Mariette, X, Pertuiset, E, Belanger, C, Janvier, M, & Chevret, S. Brouet JC & Ravaud P; Group Myelome-Autogreffe. ((2005). High-dose therapy and autologous blood stemcell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol, 20;, 23(36), 9227-33.

[22] Gay, F, Hayman, S. R, Lacy, M. Q, Buadi, F, Gertz, M. A, Kumar, S, Dispenzieri, A, Mikhail, J. R, Bergsagel, P. L, Dingli, D, Reeder, C. B, Lust, J. A, Russell, S. J, Roy, V, Zeldenrust, S. R, Witzig, T. E, Fonseca, R, Kyle, R. A, & Greipp, P. R. Stewart AK & Rajkumar SV. ((2010). Lenalidomide plus dexamethasone versus thalidomide plus
dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood., 115(7), 1343-50.

[23] Gay, F, Rajkumar, S. V, Coleman, M, Kumar, S, Mark, T, Dispenzieri, A, Pearse, R, Gertz, M. A, Leonard, J, Lacy, M. Q, Chen-kiang, S, Roy, V, Jayabalan, D. S, Lust, J. A, Witzig, T. E, Fonseca, R, Kyle, R. A, & Greipp, P. R. Stewart AK & Niesvizky R. ((2010). Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol., 85(9), 664-9.

[24] Harousseau, J. L, Attal M & Avet-Loiseau H. ((2009). The role of complete response in multiple myeloma. Blood., 114(15), 3139-46.

[25] Harousseau, J. L, Attal, M, Avet-loiseau, H, Marit, G, Caillot, D, Mohty, M, Lenain, P, Hulin, C, Facon, T, Casassus, P, Michallet, M, Maisonneuve, H, Benboubker, L, Maloisel, F, Petillon, M. O, & Webb, I. Mathiot C & Moreau Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol., 28(30):4621-9., 2010.

[26] Harousseau, J. L, Attal, M, Avet-loiseau, H, Marit, G, Caillot, D, Mohty, M, Lenain, P, Hulin, C, Facon, T, Casassus, P, Michallet, M, Maisonneuve, H, Benboubker, L, Maloisel, F, Petillon, M. O, & Webb, I. Mathiot C & Moreau Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol., 28(30):4621-9., 2010.

[27] Harousseau, J. L, Attal, M, Leleu, X, Troncy, J, Pegourie, B, Stoppa, A. M, Hulin, C, Benboubker, L, Fuzibet, J. G, & Renaud, M. Moreau P & Avet-Loiseau H. ((2006). Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica., 91(11), 1498-505.

[28] Haslett, P. A, & Hanekom, W. A. Muller G & Kaplan G. ((2003). Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis., 187(6), 946-55.

[29] Hideshima, T, Chauhan, D, Shima, Y, Raje, N, Davies, F. E, Tai, Y. T, Treon, S. P, Lin, B, Schlossman, R. L, Richardson, P, & Muller, G. Stirling DI & Anderson KC. ((2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood., 96(9), 2943-50.

[30] Hideshima, T, Chauhan, D, Shima, Y, Raje, N, Davies, F. E, Tai, Y. T, Treon, S. P, Lin, B, Schlossman, R. L, Richardson, P, & Muller, G. Stirling DI & Anderson KC. ((2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood., 96(9), 2943-50.

[31] Hideshima, T, Richardson, P, Chauhan, D, Palombella, V. J, & Elliott, P. J. Adams J &Anderson KC. ((2001). The proteasome inhibitor PS-341 inhibits growth, induces
apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 61(7), 3071-6.

[32] Hulin, C, Facon, T, Rodon, P, Pegourie, B, Benboubker, L, Doyen, C, Dib, M, Guillerem, G, Salles, B, Eschard, J. P, Lenain, P, Casassus, P, Azaïs, I, Decaux, O, Garderet, L, Mathiot, C, Fontan, J, & Lafon, I. Virion JM & Moreau Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol., 27(22):3664-70., 2009.

[33] Jagannath, S, Barlogie, B, Berenson, J, Siegel, D, Irwin, D, Richardson, P. G, Niesviz-ky, R, Alexanian, R, Limentani, S. A, Alsina, M, Adams, J, Kauffman, M, & Esseltine, D. L. Schenkein DP & Anderson KC. ((2004). A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol., 127(2), 165-72.

[34] Jagannath, S, Durie, B. G, Wolf, J, Camacho, E, Irwin, D, Lutzky, J, Mckinley, M, Gabayen, E, & Mazumder, A. Schenkein D&Crowley J. ((2005). Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol., 129(6), 776-83.

[35] Jagannath, S, Richardson, P. G, Sonneveld, P, Schuster, M. W, Irwin, D, Stadtmauer, E. A, Facon, T, & Harousseau, J. L. Cowan JM & Anderson KC. ((2007). Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia,, 21(1), 151-7.

[36] Jakubowiak, A. J, Griffith, K. A, Reece, D. E, Hofmeister, C. C, Lonial, S, Zimmerman, T. M, Campagnaro, E. L, Schlossman, R. L, Laubach, J. P, Raje, N. S, Anderson, T, Mietzel, M. A, Harvey, C. K, Wear, S. M, Barrickman, J. C, Tendler, C. L, Esseltine, D. L, Kelley, S. L, & Kaminski, M. S. Anderson KC & Richardson PG. ((2011). Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood,, 118(3), 535-43.

[37] Jakubowiak, A. J, Kendall, T, Al-zoubi, A, Khaled, Y, Mineishi, S, Ahmed, A, Campagnaro, E, Brozo, C, & Braun, T. Talpaz M & Kaminski MS. ((2009). Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol., 27(30), 5015-22.

[38] Kastritis, E, Zervas, K, Symeonidis, A, Terpos, E, Delimbassi, S, Anagnostopoulos, N, Michali, E, Zomas, A, Katodritou, E, Gika, D, Pouli, A, Christoulas, D, Roussou, M, & Kartasis, Z. Economopoulos T & Dimopoulos MA. (2009). Improved survival of pa-tients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia, , 23(6), 1152-7.

[39] Koreth, J, Cutler, C. S, Djulbegovic, B, Behl, R, Schlossman, R. L, Munshi, N. C, Rich-ardson, P. G, & Anderson, K. C. Soiffer RJ & Alyea EP 3rd. ((2007). High-dose ther-apy with single autologous transplantation versus chemotherapy for newly
diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant, 13(2), 183-96.

[40] Kumar, S, Dispenzieri, A, Lacy, M. Q, Hayman, S. R, Buadi, F. K, Gastineau, D. A, Litzow, M. R, Fonseca, R, & Roy, V. Rajkumar SV & Gertz MA. ((2007). Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia, 21, 2035-42.

[41] Kumar, S, Flinn, I, Richardson, P. G, Hari, P, Callander, N, Noga, S. J, Stewart, A. K, Turturro, F, Rifkin, R, Wolf, J, Estevam, J, Mulligan, G, & Shi, H. Webb IJ & Rajkumar SV. ((2012). Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119(19), 4375-82.

[42] Kumar, S, Giralt, S, Stadtmauer, E. A, Harousseau, J. L, Palumbo, A, Bensinger, W, Comenzo, R. L, Lentzsch, S, Munshi, N, & Niesvizky, R. San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG & Rajkumar SV; International Myeloma Working Group. ((2009). Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood, 114(9), 1729-35.

[43] Kumar, S. K, Rajkumar, S. V, Dispenzieri, A, Lacy, M. Q, Hayman, S. R, Buadi, F. K, Zeldenrust, S. R, Dingli, D, Russell, S. J, Lust, J. A, & Greipp, P. R. Kyle RA & Gertz MA. ((2008). Improved survival in multiple myeloma and the impact of novel thera­pies. Blood, 111(5), 2516-20.

[44] Kyle RA & Rajkumar SV(2004). Multiple myeloma. N Engl J Med., 351(18), 1860-73.

[45] Lokhorst, H. M, Schmidt-wolf, I, Sonneveld, P, Van Der Holt, B, Martin, H, Barge, R, Bertsch, U, Schlenzka, J, Bos, G. M, Croockewit, S, Zweegman, S, Breitkreutz, I, Joosten, P, Scheid, C, Van Marwijk-kooy, M, Salwender, H. J, Van Oers, M. H, Schaafsma, R, Naumann, R, Sinnige, H, Blau, I, Delforge, M, De Weerdt, O, Wijermans, P, Wittebol, S, & Duerssen, U, Vellenga E & Goldschmidt H; Dutch-Belgian HOVON; German GMMG. ((2008). Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica., 93(1), 124-7.

[46] Lokhorst, H. M, Van Der Holt, B, Zweegman, S, Vellenga, E, Croockewit, S, & Van Oers, M. H. von dem Borne P, Wijermans, P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R & Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). ((2010). A randomized phase 3 study on the effect of thalidomide combined with adriamycin,dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood, 115(6), 1113-20.
[47] Ludwig, H, Bekscac, M, Bladé, J, Cavenagh, J, Cavo, M, Delforge, M, Dimopoulos, M, Drach, J, Einsele, H, Facon, T, Goldschmidt, H, Harousseau, J. L, Hess, U, & Kropff, M. Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P & Palumbo A. ((2011). Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist,, 16(4), 388-403.

[48] Ludwig, H, Hajek, R, Tóthová, E, Drach, J, Adam, Z, Labar, B, Egyed, M, Spicka, I, Gisslinger, H, Greil, R, & Kuhn, I. Zojer N & Hinke A. ((2009). Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood,, 113(15), 3435-42.

[49] Mateos MV & San Miguel JFOld and new treatments in non-transplant candidate newly diagnosed MM patients. Hematology education programme fort he annual congress of the European Hematology Association. ((2012). Haematologica,, 6(1), 221-227.

[50] Mateos, M. V, Oriol, A, Martínez-lópez, J, Gutiérrez, N, Teruel, A. I, De Paz, R, García-laraña, J, Bengoechea, E, Martín, A, Mediavilla, J, D, Palomera, L, De Arriba, F, González, Y, Hernández, J. M, Sureda, A, Bello, J. L, Bargay, J, Peñalver, F. J, Ribera, J. M, Martín-mateos, M. L, García-sanz, R, Cibeira, M. T, Ramos, M. L, Vidriales, M. B, Paiva, B, Montalbán, M. A, & Lahuerta, J. J. Bladé J & Miguel JF.Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol.,, 11(10), 934-41.

[51] Mateos, M. V, Oriol, A, Martínez-lópez, J, Gutiérrez, N, Teruel, A. I, De Paz, R, García-laraña, J, Bengoechea, E, Martín, A, Mediavilla, J, D, Palomera, L, De Arriba, F, González, Y, Hernández, J. M, Sureda, A, Bello, J. L, Bargay, J, Peñalver, F. J, Ribera, J. M, Martín-mateos, M. L, García-sanz, R, Cibeira, M. T, Ramos, M. L, Vidriales, M. B, Paiva, B, Montalbán, M. A, & Lahuerta, J. J. Bladé J & Miguel JF. ((2010). Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol., 11(10), 934-41.

[52] Mateos, M. V, Richardson, P. G, Schlag, R, Khuageva, N. K, Dimopoulos, M. A, Shpillar, O, Kropff, M, Spicka, I, Petrucci, M. T, Palumbo, A, Samoilova, O. S, Dmoszynska, A, Abdulkadyrov, K. M, Schots, R, Jiang, B, Esseltine, D. L, Liu, K, & Cakana, A. van de Velde H & San Miguel JF. ((2010). Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol., 28(13), 2259-66.
[53] Mazumder, A, Kaufman, J, Niesvizky, R, & Lonial, S. Vesole D & Jagannath S. ((2008). Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia, 22(6), 1280-1.

[54] Mitsiades, N, Mitsiades, C. S, Poulaki, V, Chauhan, D, Richardson, P. G, Hideshima, T, & Munshi, N. C. Treon SP & Anderson KC. (2002). Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99(12), 4525-30.

[55] Moreau, P, Avet-loiseau, H, Facon, T, Attal, M, Tiab, M, Hulin, C, Doyen, C, Garderet, L, Randriamalala, E, Araujo, C, Lepeu, G, Marit, G, Caillot, D, Escoffre, M, Lioure, B, Benboubker, L, Pégourié, B, Kolb, B, Stoppa, A. M, Fuzibet, J. G, Decaux, O, Dib, M, Berthou, C, Chaleteix, C, Sebban, C, Traullé, C, Fontan, J, Wetterwald, M, & Lenain, P. Mathiot C & Harousseau JL. (2011). Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 118(22), 5752-8.

[56] Moreau, P, Hulin, C, Marit, G, Caillot, D, Facon, T, Lenain, P, Berthou, C, Pégourié, B, Stoppa, A. M, Casassus, P, Michallet, M, Benboubker, L, Maisonneuve, H, Doyen, C, Leyvraz, S, Mathiot, C, & Avet-loiseau, H. Attal M & Harousseau JL; IFM group. (2010). Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia, 24(6), 1233-5.

[57] Morgan, G. J, Davies, F. E, Gregory, W. M, Bell, S. E, & Szubert, A. J. Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH & Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. (2012). Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica, 97(3), 442-50.

[58] Morgan, G. J, Davies, F. E, Gregory, W. M, Russell, N. H, Bell, S. E, & Szubert, A. J. Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH & Child JA; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 118(5), 1231-8.

[59] Niesvizky, R, Flinn, I. W, Rifkin, R. M, Gabrail, N. Y, Charu, V, Clowney, B, Essell, J, Gaffar, Y. A, Warr, T. A, & Neuwirth, R, Corzo D & Reeves JA. (2010). Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients. Blood (ASH Annual Meeting Abstracts) 116: Abstract 619.
[60] Palumbo A & Anderson K(2011). Multiple myeloma. N Engl J Med., 364(11), 1046-60.

[61] Palumbo, A, Bringhen, S, Caravita, T, Merla, E, Capparella, V, Callea, V, Cangialosi, C, Grasso, M, Rossini, F, Galli, M, Catalano, L, Zamagni, E, Petrucci, M. T, De Stefano, V, Ceccarelli, M, Ambrosini, M. T, Avonto, I, Falco, P, Ciccone, G, & Liberati, A. M. Musto P & Boccadoro M; Italian Multiple Myeloma Network, GIMEMA. ((2006). Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367(9513), 825-31.

[62] Palumbo, A, Bringhen, S, Liberati, A. M, Caravita, T, Falcone, A, Callea, V, Montanaro, M, Ria, R, Capaldi, A, Zambello, R, Benevolo, G, Cerri, A, Dore, F, Cavallo, F, Gay, F, Falco, P, Ciccone, G, & Musto, P. Cavo M & Boccadoro M. ((2008). Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 112(8), 3107-14.

[63] Palumbo, A, Bringhen, S, Ludwig, H, Dimopoulos, M. A, Bladé, J, Mateos, M. V, Rosiñol, L, Boccadoro, M, Cavo, M, Lokhorst, H, Zweegman, S, Terpos, E, Davies, F, Driessen, C, Gimsing, P, Gramatzki, M, Hájek, R, & Johnsen, H. E. Leal Da Costa F, Sezer O, Spencer A,Beksac M, Morgan G, Einsele H, San Miguel JF & Sonneveld Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 118(17):4519-29., 2011.

[64] Palumbo, A, Bringhen, S, Rossi, D, Cavalli, M, Larocca, A, Ria, R, Offidani, M, Patriarca, F, Nozzoli, C, Guglielmelli, T, Bencivelli, G, Callea, V, Baldini, L, Morabito, F, Grasso, M, Leonardi, G, Rizzo, M, Falcone, A. P, Gottardi, R, Montefusco, V, Misto, P, & Petrucci, M. T, Ciccone G & Boccadoro M. ((2010). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol., 28(34), 5101-9.

[65] Palumbo, A, Giaccone, L, Bertola, A, Pregno, P, Bringhen, S, Rus, C, Triolo, S, & Gall, E. Pieli A & Boccadoro M. ((2001). Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica., 86(4), 399-403.

[66] Palumbo, A, Hajek, R, Delforge, M, Kroppf, M, Petrucci, M. T, Catalano, J, Gisslinger, H, Wiktór-jedrzejczak, W, Zodelava, M, Weisel, K, Cascavilla, N, Iosava, G, Cavo, M, Kloczko, J, Bladé, J, Beksaç, M, Spicka, I, Plesner, T, Radke, J, & Langer, C. Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C & Dimopoulos MA; MM-015 Investigators. ((2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med., 366(19), 1759-69.

[67] Paripati, H, Stewart, A. K, Cabou, S, Dueck, A, Zepeda, V. J, Pirooz, N, Ehlenbeck, C, Reeder, C, Slack, J, Leis, J. F, Boesiger, J, & Torloni, A. S. Fonseca R & Bergsagel PL. ((2008). Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia, 22(6), 1282-4.
[68] Pönisch, W, Andrea, M, Wagner, I, Hammerschmidt, D, Kreibich, U, Schwarzer, A, Zehrfeld, T, Schwarz, M, Winkelmann, C, Petros, S, & Bachmann, A. Lindner T & Niederwieser D. ((2012). Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol., 138(8), 1405-12.

[69] Pönisch, W, Mitrou, P. S, Merkle, K, Herold, M, Assmann, M, Wilhelm, G, Dachselt, K, Richter, P, Schirmer, V, Schulze, A, Subert, R, Harksel, B, Grobe, N, Stelzer, E, Schulze, M, Bittich, A, Freund, M, Pasold, R, & Friedrich, T. Helbig W & Niederwieser D; East German Study Group of Hematology and Oncology (OSHO). ((2006). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol., 132(4), 205-12.

[70] Popat, R, Oakervee, H. E, Hallam, S, Curry, N, Odeh, L, Foot, N, Esseltine, D. L, & Drake, M. Morris C & Cavenagh JD. ((2008). Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol., 141(4), 512-6.

[71] Popat, U, Saliba, R, Thandi, R, Hosing, C, Qazilbash, M, Anderlini, P, Shpall, E, Mcmannis, J, Körbling, M, Alousi, A, Andersson, B, Nieto, Y, Kebría, P, Khouri, I, De Lima, M, Weber, D, Thomas, S, Wang, M, & Jones, R. Champlin R & Giralt S. ((2009). Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant, 15, 718-23.

[72] Rajkumar, S. V, Blood, E, & Vesole, D. Fonseca R & Greipp PR; Eastern Cooperative Oncology Group. ((2006). Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol., 24(3), 431-6.

[73] Rajkumar, S. V, Hayman, S, Gertz, M. A, Dispenzieri, A, Lacy, M. Q, Greipp, P. R, Geyer, S, Iturria, N, Fonseca, R, & Lust, J. A. Kyle RA & Witzig TE. ((2002). Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol., 20(21), 4319-23.

[74] Rajkumar, S. V, Hayman, S. R, Lacy, M. Q, Dispenzieri, A, Geyer, S, M, Kabat, B, Zeldennrust, S. R, Kumar, S, Greipp, P. R, Fonseca, R, Lust, J. A, Russell, S. J, & Kyle, R. A. Witzig TE & Gertz MA. ((2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood., 106(13), 4050-3.

[75] Rajkumar, S, Jacobus, S, Callander, N. S, Fonseca, R, Vesole, D. H, Williams, M. E, Abonour, R, & Siegel, D. S. Katz M & Greipp PR; Eastern Cooperative Oncology Group. ((2010). Lenalidomide plus high-dose dexamethasone versus lenalidomide
plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol., 11(1), 29-37.

[76] Rajkumar, S. V, Rosiñol, L, Hussein, M, Catalano, J, Jedrzejczak, W, Lucy, L, Oles-nyckyj, M, Yu, Z, & Knight, R Zeldis JB & Bladé J. ((2008). Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol., 26(13), 2171-7.

[77] Rajkumar, S. V. (2012). Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol., 87(1), 78-88.

[78] Reeder, C. B, Reece, D. E, Kukreti, V, Chen, C, Trudel, S, Hentz, J, Noble, B, Pirooz, N. A, Spong, J. E, Piza, J. G, Zepeda, V. H, Mikhael, J. R, Leis, J. F, & Bergsagel, P. L. Fonseca R & Stewart AK. ((2009). Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia., 23(7), 1337-41.

[79] Richardson, P. G, Barlogie, B, Berenson, J, Singhal, S, Jagannath, S, Irwin, D, Rajkumar, S. V, Hideshima, T, Xiao, H, & Esseltine, D. Schenkein D & Anderson KC; SUM-MIT Investigators. (2005). Clinical factors predictive of outcome with bortezomib in patients with relapsed/refractory multiple myeloma. Blood., 106(9), 2977-81.

[80] Richardson, P. G, Schlossman, R. L, Weller, E, Hideshima, T, Mitsuades, C, & Davies, F. LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J & Anderson KC. (2002). Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood., 100(9), 3063-7.

[81] Richardson, P. G, Sonneveld, P, Schuster, M. W, Irwin, D, Stadtmauer, E. A, Facon, T, Harousseau, J. L, Ben-yehuda, D, Lonial, S, Goldschmidt, H, Reece, D, San-miguel, J. F, Bladé, J, Boccadoro, M, Cavenagh, J, Dalton, W. S, Boral, A. L, Esseltine, D. L, & Porter, J. B. Schenkein D & Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med., 352(24), 2487-98.

[82] Richardson, P. G, Weller, E, Lonial, S, Jakubowiak, A. J, Jagannath, S, Raje, N. S, Avigan, D. E, Xie, W, Ghobrial, I. M, Schlossman, R. L, Mazumder, A, Munshi, N. C, Vesole, D. H, Joyce, R, Kaufman, J. L, Doss, D, Warren, D. L, Lunde, L. E, Kaster, S, Delaney, C, Hideshima, T, Mitsuades, C. S, & Knight, R. Esseltine DL & Anderson KC. ((2010). Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood., 116(5), 679-86.

[83] Richardson, P. G, Xie, W, Mitsuadies, C, Chanana-khan, A. A, Lonial, S, Hassoun, H, Avigan, D. E, Oaklander, A. L, Kuter, D. J, Wen, P. Y, Kesari, S, Briemberg, H. R, Schlossman, R. L, Munshi, N. C, Heffner, L. T, Doss, D, Esseltine, D. L, & Weller, E. Anderson KC & Amato AA. (2009). Single-agent bortezomib in previously untreated
multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol., 27(21), 3518-25.

[84] Rosiñol, L, Oriol, A, Mateos, M. V, Sureda, A, García-sánchez, P, Gutiérrez, N, Alegre, A, Lahuerta, J. J, De La Rubia, J, Herrero, C, & Liu, X. Van de Velde H, San Miguel J & Bladé J. (2007). Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol., 25(28), 4452-8.

[85] Rosiñol, L, Oriol, A, Teruel, A. I, Hernández, D, López-jiménez, J, De La Rubia, J, Granell, M, Besalduch, J, Palomera, L, González, Y, Etxebeste, M. A, Díaz-mediavilla, J, Hernández, M. T, De Arriba, F, Gutiérrez, N. C, Martín-ramos, M. L, Cibeira, M. T, Mateos, M. V, Martínez, J, Alegre, A, & Lahuerta, J. J. San Miguel J & Bladé J; on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. (2012). Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood., 120(8), 1589-1596.

[86] San Miguel JFSchlag R, Khaugeva NK, Dimopoulos MA, Shpilberg O, Kropff M,Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schrots R, Jiang B, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H & Richardson PG; VISTA Trial Investigators. (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med., 359(9), 906-17.

[87] Singhal, S, Mehta, J, Desikan, R, Ayers, D, Roberson, P, Eddlemon, P, Munshi, N, Anaissie, E, Wilson, C, & Dhodapkar, M. Zeddis J& Barlogie B. (1999). Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med., 341(21), 1565-71.

[88] Sonneveld, P, Schmidt-wolf, I. G, Van Der Holt, B, El Jarari, L, Bertsch, U, Salwender, H, Zweegman, S, Vellenga, E, Broyl, A, Blau, I. W, Weisel, K. C, Wittebol, S, Bos, G, M, Stevens-kroef, M, Scheid, C, Pfreundschuh, M, Hose, D, Jauch, A, Van Der Velde, H, Raymakers, R, Schaafsma, M. R, Kersten, M. J, Van Marwijk-kooy, M, Duehrsen, U, Lindemann, W, & Wijermans, P. W. Lokhorst HM & Goldschmidt HM. (2012). Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol., 30(24), 2946-55.

[89] Sonneveld, P, Schmidt-wolf, I. G, Van Der Holt, B, El Jarari, L, Bertsch, U, Salwender, H, Zweegman, S, Vellenga, E, Broyl, A, Blau, I. W, Weisel, K. C, Wittebol, S, Bos, G, M, Stevens-kroef, M, Scheid, C, Pfreundschuh, M, Hose, D, Jauch, A, Van Der Velde, H, Raymakers, R, Schaafsma, M. R, Kersten, M. J, Van Marwijk-kooy, M, Duehrsen, U, Lindemann, W, & Wijermans, P. W. Lokhorst HM& Goldschmidt HM. (2012). Bortezomib Induction and Maintenance Treatment in Patients With Newly Diag-
nosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol. 2012 Aug 20; 30(24), 2946-55.

[90] Waage, A, Gimsing, P, Fayers, P, Abildgaard, N, Ahlberg, L, Björkstrand, B, Carlson, K, Dahl, I. M, Forsberg, K, Gulbrandsen, N, Haukås, E, Hjertner, O, Hjorth, M, Karlsson, T, Knudsen, L. M, Nielsen, J. L, Linder, O, Mellqvist, U. H, Nesthus, I, Rolke, J, Strandberg, M, Sorbø, J. H, & Wisløff, F. Juliusson G & Turesson I; Nordic Myeloma Study Group. ((2010). Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood, , 116(9), 1405-12.

[91] Wang, M, Giralt, S, & Delasalle, K. Handy B & Alexanian R. ((2007). Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, , 12(3), 235-9.

[92] Wijermans, P, Schaafsma, M, Termorshuizen, F, Ammerlaan, R, Wittebol, S, Sinnige, H, & Zweegman, S. van Marwijk Kooy M, van der Griend R, Lokhorst H & Sonneveld P; Dutch-Belgium Cooperative Group HOVON. ((2010). Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol., , 28(19), 3160-6.

[93] Zavrski, I, Krebbel, H, Wildemann, B, Heider, U, & Kaiser, M. Possinger K & Sezer O. ((2005). Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun., , 333(1), 200-5.

[94] Zonder, J. A, Crowley, J, Hussein, M. A, & Bolejack, V. Moore DF Sr, Whittenberger BF,Abidi MH, Durie BG & Barlogie B. ((2010). Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood, , 116(26), 5838-41.